Format

Send to

Choose Destination
Elife. 2018 Feb 28;7. pii: e30496. doi: 10.7554/eLife.30496.

The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes.

Author information

1
Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
2
Laboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
3
Centre d'Immunologie de Marseille-Luminy 13288, Aix Marseille Université UM2, Marseille, France.
4
Ragon Institute of MGH, MIT and Harvard University, Cambridge, United States.
5
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, United States.
6
Department of Haematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands.
#
Contributed equally

Abstract

Cytotoxic CD4 (CD4CTX) T cells are emerging as an important component of antiviral and antitumor immunity, but the molecular basis of their development remains poorly understood. In the context of human cytomegalovirus infection, a significant proportion of CD4 T cells displays cytotoxic functions. We observed that the transcriptional program of these cells was enriched in CD8 T cell lineage genes despite the absence of ThPOK downregulation. We further show that establishment of CD4CTX-specific transcriptional and epigenetic programs occurred in a stepwise fashion along the Th1-differentiation pathway. In vitro, prolonged activation of naive CD4 T cells in presence of Th1 polarizing cytokines led to the acquisition of perforin-dependent cytotoxic activity. This process was dependent on the Th1 transcription factor Runx3 and was limited by the sustained expression of ThPOK. This work elucidates the molecular program of human CD4CTX T cells and identifies potential targets for immunotherapy against viral infections and cancer.

KEYWORDS:

Runx3; T-bet; Th1 differentiation; ThPOK; cytomegalovirus; cytotoxic CD4 T cell; human; immunology; inflammation

Conflict of interest statement

YS, CG, BH, MD, TV, AA, AD, AH, JD, MB, EP, TT, EC, Kv, MD, FF, SG, AM No competing interests declared

Supplemental Content

Full text links

Icon for eLife Sciences Publications, Ltd Icon for PubMed Central
Loading ...
Support Center